BioWin presents its 2018 annual report. Find out more about the strategic and operational actions carried out by our team in R&D, international development, training, technology platforms and communication.
Introduction from Philippe Denoël, Chairman of the Board of BioWin and Head of External R&D at GSK
2018 was an exciting year for the BioWin cluster, as it rolled out the Smart Specialisation Strategy. BioWin concentrated its efforts and resources on the six domains of strategic importance for growth in Wallonia: (bio)pharmacy, cell therapy, radiation applied to health, biomanufacturing, medical devices & in vitro diagnostics, and data science. The aim is to promote scientific excellence and to support high impact research and innovation in the region. Think tanks have been set up in areas such as clinical
innovation and foreign investment strategy for Wallonia, which are designed to feed this strategic approach.
At the European level, thanks to a fresh vision for its portfolio and sustained efforts to strengthen its short and long-term leadership, BioWin has successfully been involved in different projects in the MedTech field. MAGIA brings together Lyonbiopôle, BioPmed, BioWin and Life Science Nord to promote the internationalisation of their PMEs, particularly towards the US and China, which the project has identified as their preferred markets. The S3martMed project provides a strategy to work across top European clusters in the medical technologies field and, in the long-term, will enable PMEs to create strong partnerships. The
project’s 5 partner clusters are Lyonbiopole, BioWin, BioPmed, GAPR-Medsilesia and Bioregion STERN. With SAFE N MEDTECH, a H2020 EU Framework programme on Nanotechnologies, Advanced Materials, Biotechnology and Advanced manufacturing and Processing, BioWin integrates with a group of more than 30 MedTech partners as a third party via the
Council for European BioRegion (CEBR). BioWin is, itself, taking part in the NEMS4Bio (Nano-Enabled Micro Systems for Bio-Analysis) project led by IMEC (Flanders) and including East Netherlands, Emilia Romagna, Navarra, Tampere and Auvergne Rhône-Alpes. As Chair of the Walloon Region Health Working Group, BioWin has been in the forefront of defining a regional approach towards European programmes such as H2020 and Horizon Europe.